Syngene International Limited has informed the Exchange regarding voting results of Postal Ballot
SYNGENE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved in line with Nifty Smallcap 250 and in line with its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Syngene International shareholders approved all five special resolutions via postal ballot with high participation (about 90% of equity voted). The key resolution confirmed the appointment of Mr. Peter Bains as the new Managing Director and CEO, with remuneration capped at 7% of net profits, passing with 97.36% support. Two new independent directors, Dr. Sanjaya Singh and Mr. Suresh Narayanan, were also appointed with near-unanimous approval of about 99.99% each. Resolutions to amend the Syngene Long Term Incentive Performance Share Plan 2023 and extend its benefits to employees of the holding and subsidiary companies were approved with around 80.68% support. Notably, institutional investors showed significant dissent of about 46% on both LTIP-related resolutions, while promoters voted entirely in favor.
Confirms a leadership transition at Syngene with Peter Bains formally taking over as MD and CEO, alongside a strengthened independent board. The strong institutional dissent on expanding the long-term incentive share pool signals governance concerns from large shareholders about stock-based compensation, which investors should monitor.